Filing Flows › Castle Biosciences (CSTL) › Q2 2025
Castle Biosciences (CSTL) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 4, 2025
Castle Biosciences (CSTL) reported revenue of $86.2M for the second quarter 2025 (Q2 2025), -0.9% from a year earlier and -2% from the quarter before. Operating margin was -4.9%, net earnings $4.5M (5.2% of revenue).
Castle Biosciences, Q2 2025: revenue $86.2M (-0.9% year over year), operating margin -4.9%, net earnings $4.5M, operating cash flow $20.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $86.2M | -2% | -0.9% |
| Operating profit | −$4.3M | — | — |
| Net earnings | $4.5M | — | — |
| Operating cash flow | $20.8M | — | -13% |
| Free cash flow | $11.6M | — | -38% |
What changed
Revenue was $86.2M in Q2 2025, down 1% year over year and down 2% from the previous quarter. Dermatologic was the largest line at 65% of revenue. Dermatologic lost $12.5M year over year (down 18%), 1539% of the total change.
Operating costs exceeded revenue by $4.3M, an operating margin of -4.9%. Total costs grew 10% against a revenue fall of 1%. The fastest-growing cost line was Cost of revenue (+21%). Net earnings were $4.5M, down 49% year over year. Non-operating items added $4.1M, -2873% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $20.8M (down 13% year over year), 460% of net earnings. Non-cash charges added back $3.4M of depreciation and amortization and $11.2M of share-based compensation. Working capital and other items added $1.7M. Capital expenditures of $9.3M left free cash flow of $11.6M.
Questions
What was Castle Biosciences' revenue in the second quarter 2025?
Castle Biosciences (CSTL) reported revenue of $86.2M for the second quarter 2025 (Q2 2025), -0.9% from a year earlier and -2% from the quarter before.
Was Castle Biosciences profitable in the second quarter 2025?
Operating loss was $4.3M (-4.9% of revenue) and net earnings $4.5M.
Source: Castle Biosciences 10-Q on SEC EDGAR.